EDITORIAL
1470 MicroRNAs in hepatocellular carcinoma treatment: Charting the path forward
Lin HT, Castaneda AFA, Krishna SG, Mumtaz K

1475 Innovative pathways allow safe discharge of mild acute pancreatitis from the emergency room
Kothari DJ, Sheth SG

1480 Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
Brilakis L, Theofilogiannakou E, Lykoudis PM

1488 Routine utilization of machine perfusion in liver transplantation: Ready for prime time?
Parente A, Sun K, Dukowski P, Shapiro AJ, Schlegel A

1494 Advancements in Barrett's esophagus detection: The role of artificial intelligence and its implications
Massironi S

REVIEW
1497 MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma
Wei QY, Jin F, Wang ZY, Li BJ, Cao WB, Sun ZY, Mo SJ

MINIREVIEWS
1524 Morphological and biochemical characteristics associated with autophagy in gastrointestinal diseases
Chang YF, Li JJ, Liu T, Wei CQ, Ma LW, Nikolenko VN, Chang WL

ORIGINAL ARTICLE
Retrospective Study
1533 Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors

Clinical Trials Study
1545 Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet

1556 Effects of Lactobacillus paracasei N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis
Hu YC, Ding XC, Liu HJ, Ma WL, Feng XY, Ma LN
<table>
<thead>
<tr>
<th>Issue</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Prospective Study</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Basic Study</strong></td>
<td></td>
</tr>
<tr>
<td>1609</td>
<td>Identification of an immune-related gene signature for predicting prognosis and immunotherapy efficacy in liver cancer via cell-cell communication</td>
<td>Li JT, Zhang HM, Wang W, Wei DQ</td>
</tr>
<tr>
<td></td>
<td><strong>META-ANALYSIS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>CASE REPORT</strong></td>
<td></td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board of World Journal of Gastroenterology, David L Morris, MD, FRCS (Ed), Professor, Department of Surgery, University of New South Wales, Sydney 2217, New South Wales, Australia. david.morris@unsw.edu.au

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xu Gao; Cover Editor: Jia-Ru Fan.
Basic Study

Silent information regulator sirtuin 1 ameliorates acute liver failure via the p53/glutathione peroxidase 4/gasdermin D axis

Xing-Nian Zhou, Quan Zhang, Hong Peng, Yu-Jie Qin, Yu-Hong Liu, Lu Wang, Ming-Liang Cheng, Xin-Hua Luo, Hong Li

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Motlagh B, Iran; Wang M, China; Xia B, China

Received: October 5, 2023
Peer-review started: October 5, 2023
First decision: December 6, 2023
Revised: December 20, 2023
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: March 21, 2024

Abstract

BACKGROUND
Acute liver failure (ALF) has a high mortality with widespread hepatocyte death involving ferroptosis and pyroptosis. The silent information regulator sirtuin 1 (SIRT1)-mediated deacetylation affects multiple biological processes, including cellular senescence, apoptosis, sugar and lipid metabolism, oxidative stress, and inflammation.

AIM
To investigate the association between ferroptosis and pyroptosis and the upstream regulatory mechanisms.

METHODS
This study included 30 patients with ALF and 30 healthy individuals who underwent serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) testing. C57BL/6 mice were also intraperitoneally pretreated with SIRT1, p53, or glutathione peroxidase 4 (GPX4) inducers and inhibitors and injected with lipopolysaccharide (LPS)/D-galactosamine (D-GaIN) to induce ALF. Gasdermin D (GSDMD)−/− mice were used as an experimental group. Histological changes in liver tissue were monitored by hematoxylin and eosin staining. ALT, AST, glutathione, reactive oxygen species, and iron levels were measured using commercial kits. Ferroptosis- and pyroptosis-related protein and mRNA expression was detected by western blot and quantitative real-time polymerase chain reaction. Ferroptosis- and pyroptosis-related protein and mRNA expression was detected by western blot and quantitative real-time polymerase chain reaction. SIRT1, p53, and GSDMD were assessed by immunofluorescence analysis.
RESULTS

Serum AST and ALT levels were elevated in patients with ALF. SIRT1, solute carrier family 7a member 11 (SLC7A11), and GPX4 protein expression was decreased and acetylated p53, p53, GSDMD, and acyl-CoA synthetase long-chain family member 4 (ACSL4) protein levels were elevated in human ALF liver tissue. In the p53 and ferroptosis inhibitor-treated and GSDMD−/− groups, serum interleukin (IL)−1β, tumour necrosis factor alpha, IL-6, IL-2 and C-C motif ligand 2 levels were decreased and hepatic impairment was mitigated. In mice with GSDMD knockout, p53 was reduced, GPX4 was increased, and ferroptotic events (depletion of SLC7A11, elevation of ACSL4, and iron accumulation) were detected. In vitro, knockdown of p53 and overexpression of GPX4 reduced AST and ALT levels, the cytotastic rate, and GSDMD expression, restoring SLC7A11 depletion. Moreover, SIRT1 agonist and overexpression of SIRT1 alleviated acute liver injury and decreased iron deposition compared with results in the model group, accompanied by reduced p53, GSDMD, and ACSL4, and increased SLC7A11 and GPX4. Inactivation of SIRT1 exacerbated ferroptotic and pyroptotic cell death and aggravated liver injury in LPS/D-GalN-induced in vitro and in vivo models.

CONCLUSION

SIRT1 activation attenuates LPS/D-GalN-induced ferroptosis and pyroptosis by inhibiting the p53/GPX4/GSDMD signaling pathway in ALF.

Key Words: Silent information regulator sirtuin 1; Ferroptosis; Pyroptosis; p53/glutathione peroxidase 4/gasdermin D; Acute liver failure

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: In this study, we investigated the involvement of ferroptosis and pyroptosis in acute liver failure (ALF) using lipopolysaccharide/D-galactosamine-induced ALF model mice. Our results showed that silent information regulator sirtuin 1 activation alleviated ALF through p53/glutathione peroxidase 4/gasdermin D, which mediated the ferroptosis and pyroptosis crosstalk. Our study established a link between ferroptosis and pyroptosis and the upstream regulatory mechanisms. These results may lead to the identification of potential therapeutic targets for ALF.

INTRODUCTION

Acute liver failure (ALF) is a rare and severe consequence of abrupt hepatocyte injury, with a mortality rate of up to 30% [1]. ALF is caused by various factors, including drugs, toxins, virus, and metabolic diseases. The central event in ALF is the excessive and uncontrolled mass death of hepatocytes through necrosis and apoptosis, which can cause DNA damage and oxidation stress, accompanied by an inflammatory storm[2,3]. Accumulating evidence has suggested that ferroptosis and pyroptosis, which are novel programmed modes of cell death that are distinct from necrosis, apoptosis, and autophagy, play critical roles in ALF by each mediating different immunological effects and inflammatory responses[4-6]. Ferroptosis is characterized by intracellular iron overload, decreased glutathione peroxidase 4 (GPX4) activity, and accumulation of lipid reactive oxygen species (ROS)[7]. Solute carrier family 7a member 11 (SLC7A11), a component of the system Xc- antipporter located in the cell membrane, is involved in glutathione (GSH) synthesis[8]. Jiang et al[9] showed that transcriptional suppression of SLC7A11 by p53 resulted in inhibited cystine uptake and sensitized cells to ferroptosis. p53 plays a critical role in the cellular response to various stresses, including DNA damage, hypoxia, nutrition starvation, and oncogene activation[10]. Additionally, p53 promotes ferroptosis by inhibiting cystine metabolism and ROS activity[9,11].

Pyroptosis is a form of lytic cell death induced by pathogen infection or an endogenous challenge[12]. When cells receive internal and external danger signals, pattern recognition receptors initiate various inflammasomes to activate caspase 1, leading to cleavage of the pyroptosis executor gasdermin D (GSDMD) into the active N terminal and inactive C terminal. The active N terminal fragment translocates from the cytosol into the medial cell membrane, forming a large number of sieve membrane pores, resulting in the release of cell contents, including interleukin (IL)−1β and IL-18, into the extracellular space. Recruitment of immune cells for targeted migration to the injury site mediates secondary immune damage[13]. Our previous study showed that GSDMD-mediated pyroptosis of hepatocytes played an important role in the pathogenesis of ALF[14]. Furthermore, GSDMD knockout reduced hepatocyte death and inflammatory responses, thus alleviating ALF. However, the relationship between ferroptosis and pyroptosis in ALF is unknown.
Silent information regulator sirtuin 1 (SIRT1), which is an NAD+-dependent protein deacetylase, regulates the acetylation of specific transcription factors and proteins, including p53. SIRT1 is involved in various functions, such as energy metabolism, stress responses, inflammation, and redox homeostasis\cite{15,16}. Deacetylation of p53 by SIRT1 may act as a protective shield in sepsis-induced liver injury\cite{17}.

In the present study, we investigated the involvement of ferroptosis and pyroptosis in ALF using lipopolysaccharide (LPS)/D-galactosamine (D-GaIN)-induced ALF model mice. Our study established an association between ferroptosis and pyroptosis and the upstream regulatory mechanisms. These results may lead to the identification of potential therapeutic targets for ALF.

**MATERIALS AND METHODS**

**Patients**

Samples from 30 patients with ALF and 30 healthy individuals were collected from the Affiliated Hospital of Guizhou Medical University. ALF was diagnosed by following the definition in the 2017 EASL ALF Guidelines\cite{18}. Whole livers of seven patients with ALF and donor trimmed portions from three liver transplant recipients were collected. This study was approved by the Ethics Committee of the Affiliated Hospital of Guizhou Medical University (2018 Lun Audit No. 036) and complied with the ethical guidelines of the 1975 Declaration of Helsinki. The tissue donors and/or their families provided informed consent for the use of human residual material for research purposes.

**Mouse model and drug treatment**

Male C57BL/6 mice (8-10 wk, 22-26 g) were purchased from SPF Biotechnology Co. (Beijing, China). Male GSDMD systemic knockout (GSDMD\textsuperscript{-/-}) mice (C57BL/6j strain, 6-8 wk) were a generous gift from Shao Feng's Laboratory, Beijing Institute of Life Sciences, China. All animals were kept in the Laboratory Animal Centre of Guizhou Medical University (laboratory animal production license No. SYXK (Guizhou) 2023-0002, and laboratory animal use license No. SYXK (Guizhou) 2023-0002). The animal experimental methods designed in this study were reviewed and approved by the Animal Ethics Committee of Guizhou Medical University. The mice were maintained in a 12-h light-dark cycle environment and had free access to water and food. The mice acclimated to the environment for 1 wk before the experiments.

The mice were randomly divided into the following nine experimental groups (n = 10 per group): Vehicle (phosphate-buffered saline), resveratrol (a SIRT1 activator; MedChemExpress, New Jersey, United States; 30 mg/kg, intraperitoneal injection (i.p.) for 14 d), EX527 (a SIRT1 inhibitor; Sigma, St. Louis, Missouri, United States; 5 mg/kg, i.p. for 14 d), pifithrin-α (a p53 inhibitor; MedChemExpress; 2.2 mg/kg, i.p. for 3 d), nutlin-3a (a p53 inducer; MedChemExpress; 12 mg/kg, i.p. for 7 d), liproxstatin-1 (a ferroptosis inhibitor; MedChemExpress; 10 mg/kg, i.p. for 14 d), RAS-selective lethal 3 (RSL3) (a ferroptosis inducer; Sigma; 2 mg/kg, i.p. for 7 d), GSDMD\textsuperscript{-/-}, and ALF model. The mice were pre-treated as described above before establishing the model.

To establish the ALF model, all groups except for the vehicle group, were injected with LPS (Sigma; 10 µg/kg, i.p.) and D-GaIN (Sigma; 300 mg/kg, i.p.). After 48 h, survival was recorded and the surviving mice were sacrificed. Blood was collected from the eyeball vein and centrifuged at 3000 g/min for 15 min. The serum was separated and stored at -80 °C.

Liver tissues were harvested by portal vein perfusion. Some of the specimens were fixed using paraformaldehyde for 48 h, and a pathological examination was performed. The remaining tissues were quickly stored at -80 °C.

**Iron assay**

Liver tissues and cells were homogenized in an ice bath using the Iron Assay Kit (BC4355; Solarbio, Beijing, China). The samples were centrifuged at 4000 × g at 4 °C and the supernatants were removed. The supernatants were added to a 96-well plate, and the absorbance was measured at 520 nm with a microplate reader.

**Hematoxylin and eosin staining**

Liver tissues were fixed in 4% paraformaldehyde for 24 h and dehydrated with a concentration gradient of ethanol solutions, followed by paraffin embedding. Tissue sections were cut, de-waxed, rehydrated, and stained with hematoxylin and eosin (HE). The sections were subjected to microscope analysis.

**Immunofluorescence analysis**

Liver tissues were collected and routinely embedded in optimal cutting temperature compound. The sections were dewaxed three times for 30 min each and dehydrated three times for 30 min each, followed by three washes with phosphate-buffered saline. Liver sections were stained with antibodies against SIRT1 (ab110304; Abcam), p53 (80077-1-RR; Proteintech), and GSDMD (ab219800; Abcam) overnight at 4 °C. After extensive washing, the sections were incubated with the respective fluorescent secondary antibodies (ab150115 and ab150077; Abcam) for 2 h at room temperature.

**Short interfering RNA transfection**

SIRT1, p53, GPX4, and negative control (NC) short interfering (siRNAs) were obtained from GeneChem (China). HL7702 cells were transfected with siRNAs using Lipofectamine 3000 (Invitrogen, United States) by following the manufacturer's instructions. After 6 h, the culture medium was replaced with fresh complete medium and the cells were cultured for 48 h.
Alanine aminotransferase and aspartate aminotransferase assays

The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum were assessed using the ALT Kit (E-BC-K235-M; Elabscience, China) and AST Kit (E-BC-K236-M; Elabscience, China) by following the manufacturers’ instructions.

ROS assay

ROS activity in cells was measured with a fluorescent probe (DCFH-DA) (Beyotime, Shanghai, China). HL7702 cells in a six-well plate were treated with D-GalN/LPS (D-GalN 15 mmol/L + LPS 100 µg/mL) for 24 h, and DCFH-DA (2 µL/well) was added for 30 min at 37 °C. The cells were washed three times with serum-free medium. DCFH-DA was measured by flow cytometric analysis.

Quantitative real-time polymerase chain reaction

Liver tissue was lysed with Trizol (Omeya, United States). Total RNA was extracted and tested for concentration and purity. The RNA was reverse transcribed using a reverse transcription kit (Takara, Japan) to synthesize cDNA. Expression levels of mRNA were evaluated using the SYBR Green detection system (Takara, Japan). All samples were measured in triplicate and gene expression was normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels. The primer sequences were as follows: GAPDH, (forward) AGTCTCGTGTGAAACGGATTTG and (reverse) GGGGTCGTTAGCGCAACA; p53, (forward) CCCCTGCATCCT TGTCCCT and (reverse) AGCTGGCAATAGCT-TATTGAG; GPX4, (forward) TGTGCACT CGCGAGTATTT and (reverse) CCGGTCGTTGAAGGA; and (reverse) AGGCTGTCACCAGGGAATG; SLC7A11, (forward) GCACCCGTCATCGGATCAG and (reverse) CTCCACAGCGACACCAGAAAA; and acyl-CoA synthetase long-chain family member 4 (ACSL4), (forward) CCTAGGCCGCTTGAATTCAC and (reverse) GTTTCGGTGAACGGATTTG.

Western blot analysis

Liver tissues and cells were rinsed twice with phosphate-buffered saline buffer and lysed on ice with RIPA lysis solution (Solarbio). The protein samples were separated on 10% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Millipore, United States). The membranes were incubated with mouse anti-Sirt1 (1:1000; Abcam; ab110304), mouse anti-p53 (1:1000; Abcam; ab26), rabbit anti-p53 (acetyl K382) (1:1000; Abcam; ab75754), mouse anti-GPX4 (1:2000; Proteintech; 67763-1-Ig), rabbit anti-GSDMD (1:1000; Abcam; ab129800), rabbit anti-SLC7A11 (1:2000; Proteintech; SA00001-1) rabbit anti-ACSL4 (1:2000; Origene; TA349566), mouse anti-p53 (1:1000; Abcam; ab26), rabbit anti-p53 (acetyl K382) (1:1000; Abcam; ab75754), mouse anti-GPX4 (1:2000; Proteintech; 67763-1-lg), mouse anti-PARP (1:1000; Proteintech; 10819-1-lg), and mouse anti-β-actin (1:2000; Proteintech; ab8227) antibodies overnight at 4 °C. The membranes were incubated with secondary anti-mouse (1:5000; Proteintech; SA00001-2) or anti-rabbit horseradish peroxidase-conjugated antibodies (1:5000; Proteintech; SA00001-2) for 2 h at room temperature. The signals were visualized using enhanced chemiluminescence (CLI;X; Chemiscop, Shanghai, China).

Statistical analysis

Statistical analyses were conducted using Prism 8.3.0 (GraphPad, United States). Values are expressed as the mean ± SD of at least three independent experiments. The normality and the homogeneity of variance were checked by the Shapiro-Wilk test before Student’s t-test and one-way analysis of variance. Student’s t-test was used to compare data between two groups, while one-way analysis of variance analysis was used for comparison among multiple groups. Statistical significance was considered if P value was < 0.05.

RESULTS

Ferroptosis and pyroptosis are triggered in liver tissue in patients with ALF

To examine the potential role of ferroptosis and pyroptosis in ALF, we first examined the inflammatory status, liver function biomarkers, and markers for ferroptosis and pyroptosis in the serum or liver tissue samples from patients with ALF. We found that AST, ALT, and inflammatory factor levels were increased in human ALF serum (Figure 1A). Alanine aminotransferase and aspartate aminotransferase (ALT) and aspartate aminotransferase (AST) in serum were assessed using the ALT Kit (E-BC-K235-M; Elabscience, China) and AST Kit (E-BC-K236-M; Elabscience, China) by following the manufacturers’ instructions.

Inhibition of p53/GPX4/GSDMD-mediated ferroptosis and the pyroptosis pathway protects mice against LPS/D-GaIN-induced ALF

We observed an induction of ferroptosis and pyroptosis in human ALF liver tissues, accompanied by increased p53 protein expression. To further examine the mechanism of ferroptosis and pyroptosis in ALF, we inhibi
Figure 1: Ferroptosis and pyroptosis occur in human acute liver failure. A: The levels of aspartate aminotransferase, alanine aminotransferase, tumour...
necrosis factor alpha, interleukin (IL)-1β, and IL-6 were changed in serum samples of healthy individuals and patients with acute liver failure (ALF) \( (n = 30 \text{ in each group}) \); B: Iron staining (scale bar: 100 µm and 33.3 µm) of normal liver tissue and ALF liver tissue; C: Detection of iron in normal liver tissue and ALF; D: Western blot analyses of glutathione peroxidase 4, solute carrier family 7a member 11, and acyl-CoA synthetase long-chain family member 4 proteins were performed in healthy individuals and patients with ALF. Data are presented as the mean ± SD of three independent experiments; E: Western blot analysis of caspase 3 protein expression \( (n = 3) \); F: Western blot analysis of caspase 3 protein expression in healthy individuals and patients with ALF \( (n = 3) \).

Furthermore, mice pre-treated with pifithrin-α or liproxstatin-1 and GSDMD-/- mice showed a reduction in elevated serum levels of IL-1β, tumour necrosis factor alpha (TNF-α), IL-6, IL-2, and C-C motif ligand 2 (CCL2), which are inflammatory factors associated with pyroptosis, compared with those in the ALF model group (Figure 2C). Western blot analysis and quantitative real-time reverse transcription PCR (qRT-PCR) showed that mice pre-treated with pifithrin-α and liproxstatin-1 had reduced protein and mRNA levels of GSDMD and ferroptotic markers (ACSL4 and p53) compared with those in the ALF model group. We also found that GSDMD-/- mice showed increased GPX4 and SLC7A11 and decreased p53 and ACSL4 expression, accompanied by a decrease in iron accumulation (Figure 2D-G). Notably, p53 protein levels were markedly lower in GSDMD-/- mice than in ALF mice, but they were not affected by liproxstatin-1. However, p53 mRNA levels in the liproxstatin-1 group were downregulated (Figure 2D). An immunofluorescence assay showed a decrease in GSDMD expression in the groups treated with pifithrin-α and liproxstatin-1 (Supplementary Figure 1A).

To gain insight into the potential mechanisms of ferroptosis and pyroptosis in ALF induced by LPS/D-GalN, HL7702 cells transfected with siRNA targeting p53 and plasmid overexpressing GPX4 were stimulated with LPS/D-GalN for 24 h. We then detected the cellular AST and ALT contents. We found that LPS/D-GalN significantly increased AST and ALT, while knocking down p53 and overexpressing GPX4 reduced AST and ALT (Figure 3A and B). We further examined iron, ROS, GSH, and lipid peroxidation products, and found that knocking down p53 and overexpressing GPX4 significantly reduced GSH, malondialdehyde, and ROS contents compared with those in the ALF model group (Figure 3C-E). Western blot analysis and qRT-PCR showed that when p53 was knocked down and GPX4 was overexpressed, SLC7A11 protein and mRNA expression levels were restored compared with control levels. This change occurred at the same time as a decrease in ACSL4 expression (Figure 3F-H). Notably, GSDMD expression was also reduced in the sh-p53 group compared with the sh-NC group. To evaluate the relationships between p53, GPX4, and GSDMD, we overexpressed GPX4 in HL7702 cells, and found that AST and ALT levels were increased (Supplementary Figure 1A). Furthermore, with GPX4 overexpression, iron, ROS, and GSH contents and ferroptotic events were downregulated compared with those in the control group (Supplementary Figure 2A). Western blot analysis and qRT-PCR showed that SLC7A11 protein and mRNA levels were downregulated, while p53, ACSL4, and GSDMD protein and mRNA levels were upregulated in the GPX4 knockdown group compared with the sh-NC group (Supplementary Figure 2B and C).

GPX4 and GSDMD play a prominent role in the occurrence of ferroptosis and pyroptosis. p53 promotes ferroptosis by inhibiting cysteine metabolism and ROS activity. However, the relationships between p53, GPX4, and GSDMD are unknown. These results showed that the suppression of ferroptosis and pyroptosis attenuated LPS/D-GalN-induced hepatocyte injury by inhibiting the p53/GPX4/GSDMD signaling pathway and lipid peroxidation.

Upregulation of p53 downregulates SLC7A11 and GPX4, leading to ferroptosis and triggering of pyroptosis

To further validate our hypothesis, we used nutlin-3α and RSL3 (ferroptosis inducer, which also causes GPX4 inactivation)\(^{21,22}\) in ALF model mice. HE staining of liver tissue showed that the administration of nutlin-3α dramatically aggravated liver injury in ALF model mice to the same extent as that with RSL3 (Figure 4A). Furthermore, both treatments shortened the survival time of mice (Figure 4B). We also found that nutlin-3α and RSL3 worsened the inflammatory response in ALF model mice (Figure 4C). GPX4 and SLC7A11 were significantly decreased after nutlin-3α treatment, and ACSL4 protein levels were elevated (Figure 4D). Notably, p53 protein levels were upregulated slightly after RSL3 treatment, but this was not significant (Figure 4D). Western blot analysis showed that GSDMD and GSDMD-N protein levels were significantly higher in the nutlin-3α and RSL3 groups than in the ALF model group (Figure 4E), accompanied by increased iron deposition (Figure 4F). Immunofluorescence staining showed that nutlin-3α and RSL3 significantly exacerbated GSDMD expression in liver tissue, which suggested that inducing ferroptosis aggravated pyroptosis (Supplementary Figure 1B). Taken together, these data indicate that p53 upregulation may cause SLC7A11 and GPX4 downregulation, leading to ferroptosis, which in turn triggers pyroptosis to amplify the inflammatory response. This process may form a positive feedback loop, resulting in the deterioration of ALF.

The SIRT1-mediated p53/GPX4/GSDMD signaling pathway is dependent on p53 deacetylation in LPS/D-GalN-induced ALF

We found that SIRT1 levels were downregulated in human ALF, while Ac-p53 and p53 Levels were increased (Figure 1D and E). Previous studies have shown that SIRT1 inhibits p53 deacetylation. Our results confirmed that p53/GPX4/ GSDMD mediated ferroptosis and pyroptosis. Therefore, we next pre-treated mice with EX527 and resveratrol. HE staining showed that the structure of the liver lobules was severely destroyed by the infiltration of inflammatory cells in the EX527 group compared with the ALF model group. In contrast, resveratrol treatment attenuated LPS/D-GalN-induced acute liver injury (Figure 5A) and prolonged the survival time of mice (Figure 5B). Multi-factor kits showed that...
Zhou XN et al. Study on the mechanism of ALF

A

B

C

D

ACS14 72 kDa
SLC7A11 55 kDa
p35 53 kDa
GFPV4 16 kDa
β-Actin 42 kDa

https://www.wjgnet.com
EX527 exacerbated the inflammatory response (serum IL-1β, TNF-α, IL-6, IL-2, and CCL2 levels in mice), while resveratrol had the opposite effect (Figure 5C). Western blot analysis showed that, in liver tissue of resveratrol-treated mice with ALF, SIRT1 activation increased p53 acetylation, with no significant changes in p53 protein levels (Figure 5D). When SIRT1 was inhibited, GPX4 and SLC7A11 expression was decreased and ACSL4 expression was upregulated (Figure 5E). GSDMD and GSDMD-N expression was increased, especially GSDMD-N (Figure 5A), and iron accumulation was enhanced (Figure 5B). We found that resveratrol, as a SIRT1 inducer, increased SIRT1 expression. In contrast, EX527 decreased SIRT1 level (Figure 5C and D). We further performed immunofluorescence experiments, which showed no significant change in p53 protein expression in the resveratrol or EX527 treatment groups compared with the ALF model group (Figure 5E and F), which is consistent with our results mentioned above (Figure 5D). Overall, these data demonstrate that SIRT1 exerts protection against ALF by inhibiting p53 deacetylation, thereby inhibiting the GPX4/GSDMD signaling pathway.

**SIRT1 attenuates hepatocyte ferroptosis and pyroptosis via a p53/GPX4/GSDMD-dependent mechanism**

To further investigate the functional role of SIRT1 in hepatocyte ferroptosis and pyroptosis, we knocked down and overexpressed SIRT1 in HL7702 cells. ALT and AST levels were lower in the SIRT1 overexpression group and higher in the SIRT1 knockdown group than in the ALF model and knockdown groups (Figure 7A and B). Ferroptotic events (elevation of ROS activity and iron accumulation) were detected in the SIRT1 overexpression group (Figure 7C and D). Western blot analysis showed that Ac-p53 protein levels were significantly decreased in the SIRT1 overexpression group, while p53 did not change (Figure 7E). We next examined ferroptosis- and pyroptosis-related proteins (GPX4, SLC7A11, ACSL4, and GSDMD). We found that upregulation of SIRT1 increased GPX4 and SLC7A11 protein expression and decreased ACSL4 and GSDMD protein expression (Figure 7F and G). Furthermore, knockdown of SIRT1 inhibited the deacetylation and degradation of p53 and downregulated the levels of SLC7A11 and GPX4 (Figure 7F and G). These data show that SIRT1 overexpression alleviated ALF in HL7702 cells via a p53/GPX4/GSDMD-dependent mechanism.

**DISCUSSION**

ALF is a life-threatening disease with high morbidity and mortality rates. The most effective treatment for ALF at present is liver transplantation[22]. However, liver transplants are not widely available because of the lack of donors and the high cost of medical care[18]. ALF is characterized by extensive hepatocellular cell death, leading to massive loss of parenchymal cells, with the release of cell contents, cell swelling, and inflammation. Emerging evidence has indicated that ferroptosis and pyroptosis, two newly identified forms of non-apoptotic cell death, play a crucial role in liver disease[24, 25], but their precise role in ALF is unknown. In this study, we provided evidence that ferroptosis and pyroptosis occurred in ALF and established an association between them. We found that SIRT1 activation or inhibition of the p53/
Figure 3 Inhibition of the p53/glutathione peroxidase 4/gasdermin D signaling pathway exacerbates acute liver injury in vitro. A and B: The levels of alanine aminotransferase and aspartate aminotransferase were changed in HL7702 cells \((n = 3)\); C-E: The levels of iron, reactive oxygen species, and glutathione were changed in HL7702 cells \((n = 3)\); F: Quantitative real-time polymerase chain reaction analyses of p53, glutathione peroxidase 4 (GPX4), solute carrier family 7a member 11 (SLC7A11), Acyl-CoA synthetase long-chain family member 4 (ACSL4), and gasdermin D (GSDMD) mRNA expression \((n = 3\) in each group); G: Western blot analyses of p53, GPX4, and GSDMD protein expression \((n = 3\) in each group); H: Western blot analyses of SLC7A11 and ACSL4 protein expression \((n = 3\) in each group). \(aP < 0.05, \ bP < 0.01\). ALF: Acute liver failure; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; IL: Interleukin; GPX4: Glutathione peroxidase 4; SLC7A11: Solute carrier family 7a member 11; ACSL4: Acyl-CoA synthetase long-chain family member 4; GSDMD: Gasdermin D; SIRT1: Silent information regulator sirtuin 1; LPS: Lipopolysaccharide; D-GalN: D-galactosamine.
Figure 4 Activation of the p53/glutathione peroxidase 4/gasdermin D signaling pathway exacerbates alanine aminotransferase. A: Macroscopic examinations of mouse livers and microscopic examinations of liver sections stained with hematoxylin and eosin (100 ×); B: Administration of nutlin-3α and RAS-selective lethal 3 shortened the survival time of mice treated with lipopolysaccharide/D-galactosamine; C: Detection of interleukin (IL)-1β, tumour necrosis factor alpha, IL-6, IL-2, and C-C motif ligand 2 in mouse serum with multi-factor kit; D: Western blot analyses of p53, glutathione peroxidase 4, solute carrier family 7a member 11, acyl-CoA synthetase long-chain family member 4, and gasdermin D (GSDMD) protein expression (n = 3 in each group); E: Western blot analyses of GSDMD protein expression (n = 3 in each group); F: Iron detection with an iron kit. aP < 0.05, bP < 0.01. ALF: Acute liver failure; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; IL: Interleukin; GPX4: Glutathione peroxidase 4; SLC7A11: Solute carrier family 7a member 11; ACSL4: Acyl-CoA synthetase long-chain family member 4; GSDMD: Gasdermin D; SIRT1: Silent information regulator sirtuin 1; LPS: Lipopolysaccharide; D-GalN: D-galactosamine; RSL3: RAS-selective lethal 3.
SIRT1 has been widely reported to play a protective role in various biological processes including nutrient starvation, DNA repair, aging, oxidative stress, and the inflammatory response[36,37]. One study suggested that negative regulation of SIRT1 increased pyroptosis (GSDMD) and aggravated the acute hepatic pro-inflammatory reaction[38]. This finding is consistent with another study, which showed that SIRT1 was suppressed in APAP-induced hepatotoxicity[39]. Treatment with resveratrol, a small-molecule SIRT1 activator, shows a protective effect in mouse liver ischemia-reperfusion injury [40,41]. Similarly, in our study, we found that SIRT1 was decreased and p53 and Ac-p53 were increased in human ALF.
SIRT1 is an NAD-dependent deacetylase that directly deacetylates p53 and mediates its function\[37\]. A study showed that SIRT1 overexpression abolished p53 acetylation levels and reduced the release of hepatic enzymes, hepatic oxidative, stress, and inflammation in non-alcoholic fatty liver disease\[42\]. Ma et al\[43\] demonstrated that SIRT1 inhibited ferroptosis-induced myocardial cell death through the p53/SLC7A11 axis in myocardial ischemia–reperfusion injury. Nevertheless, whether SIRT1 activation regulates p53 deacetylation to affect ferroptosis in ALF has not been shown. Our study showed that SIRT1 activation attenuated liver injury and the inflammatory response, accompanied by a reduction in ferroptosis and pyroptosis-related proteins in ALF. We demonstrated that SIRT1 activation inhibited p53/GPX4/GSDMD by inducing p53 acetylation, which attenuated LPS/D-GalN-induced ALF.

CONCLUSION

In conclusion, our study provides evidence that ferroptosis and pyroptosis are crucial modes of hepatocyte death in ALF, and the interactions between these modes of cell death advance the progression of ALF. SIRT1 plays an important role in ALF through p53/GPX4/GSDMD-mediated ferroptosis and pyroptosis. These results could provide new therapeutic targets to alleviate ALF. However, there are still many issues that need to be further investigated. First, p53 is a versatile protein with multiple roles in promoting physiological and pathological regulation. Although p53 can promote ferroptosis, it is also involved in several major functions, such as cell cycle arrest, DNA repair, angiogenesis, metastasis, and senescence. When p53 pro-death function is inhibited, its pro-survival function is concomitantly impaired. Therefore, how the unique p53-mediated pro-death function might be achieved is unclear. Second, our research was only limited to cellular and mouse models and has not been applied to clinical studies. Although we found decreased SIRT1 expression in human ALF liver tissue, whether an SIRT1 activator is effective for acute liver injury and failure in patients is unknown, and further safety and efficacy studies are required. Third, the mechanism of ALF may be associated with multiple modes of cell death, but our study was limited to ferroptosis and pyroptosis, and was not designed to examine other modes of death. The focus of our next study will be to further investigate the mechanism of ALF in depth.
Figure 7 Silent information regulator sirtuin 1 attenuates hepatocyte ferroptosis and pyroptosis via a p53/glutathione peroxidase
**4/gasdermin D dependent mechanism in vitro.** A and B: The levels of aspartate aminotransferase and alanine aminotransferase were changed in serum samples of HL7702 cells (n = 3); C and D: The levels of iron and reactive oxygen species were changed in HL7702 cells (n = 3); E: Western blot analyses of silent information regulator sirtuin 1, p53, and acetylated p53 protein expression (n = 3 in each group); F: Western blot analyses of gasdermin D and glutathione peroxidase 4 protein expression (n = 3 in each group); G: Western blot analyses of solute carrier family 7a member 11 and Acyl-CoA synthetase long-chain family member 4 protein expression (n = 3 in each group). *P < 0.05, *P < 0.01. ALF: Acute liver failure; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; IL: Interleukin; GPX4: Glutathione peroxidase 4; SLC7A11: Solute carrier family 7a member 11; ACSL4: Acyl-CoA synthetase long-chain family member 4; GSDMD: Gasdermin D; SIRT1: Silent information regulator sirtuin 1; LPS: Lipopolysaccharide; D-GalN: D-galactosamine; RSL3: RAS-selective lethal 3; ROS: Reactive oxygen species.

**Figure 8** Silent information regulator sirtuin 1 activation ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by inhibiting p53/glutathione peroxidase 4/gasdermin D to reduce ferroptosis and pyroptosis. Silent information regulator sirtuin 1 activation inhibits p53 deacetylation, thereby inhibiting the glutathione peroxidase 4 (GPX4)/gasdermin D (GSDMD) signaling pathway and reducing inflammatory response and iron deposition. Blocking the p53/GPX4/GSDMD signaling pathway attenuates ferroptosis and pyroptosis in acute liver failure. IL: Interleukin; GPX4: Glutathione peroxidase 4; SLC7A11: Solute carrier family 7a member 11; GSDMD: Gasdermin D; SIRT1: Silent information regulator sirtuin 1; ROS: Reactive oxygen species; GSH: Glutathione; TNF-α: Tumour necrosis factor alpha.

**ARTICLE HIGHLIGHTS**

**Research background**

Acute liver failure (ALF) has a high mortality with widespread hepatocyte death involving ferroptosis and pyroptosis, but their precise role in ALF is unknown. Silent information regulator sirtuin 1 (SIRT1)-mediated deacetylation influences multiple biological processes, including cellular senescence, apoptosis, sugar and lipid metabolism, oxidative stress, and inflammation. In this study, we examined the link between ferroptosis and pyroptosis and the upstream regulatory mechanisms.

**Research motivation**

The most effective treatment for ALF at present is liver transplantation. However, liver transplants are not widely available because of the lack of donors and the high cost of medical care. Therefore, therapies for ALF are imminent.
Zhou XN et al. Study on the mechanism of ALF

Research objectives
To explore the link between ferroptosis and pyroptosis and the upstream regulatory mechanisms.

Research methods
Animal and cellular models of ALF were developed. The levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were tested with automatic biochemistry instrument. Iron, reactive oxygen species, and glutathione levels were measured using commercial kits. SIRT1, p53, acylated p53 (Ac-p53), glutathione peroxidase 4 (GPX4), gasdermin D (GSDMD), solute carrier family 7a member 11 (SLC7A11), and acyl-CoA synthetase long-chain family member 4 (ACSL4) protein expression levels were measured through Western blot analysis.

Research results
AST and ALT levels were elevated in the serum of ALF patients. SIRT1, SLC7A11, and GPX4 expressions were decreased and Ac-p53, p53, GSDMD, and ACSL4 levels were elevated in human ALF liver tissue. In p53 and ferroptosis inhibitor–treated and GSDMD−/− groups, serum interleukin (IL)-1β, tumour necrosis factor alpha, IL-6, IL-2, and C-C motif ligand 2 levels were decreased and hepatic impairment was mitigated. In mice with GSDMD knockout, p53 was reduced, GPX4 was increased, and ferroptotic events (depletion of SLC7A11, elevation of ACSL4, and iron accumulation) were detected.

Research conclusions
SIRT1 activation attenuates lipopolysaccharide/D-galactosamine-induced ferroptosis and pyroptosis by inhibiting the p53/GPX4/GSDMD signaling pathway in ALF.

Research perspectives
Our research is only limited to cellular and mouse models and has not been applied to clinical studies. Although we found decreased SIRT1 expression in human ALF liver tissue, whether SIRT1 activator is effective for acute liver injury and failure in patients is unknown, and further safety and efficacy studies are required.

ACKNOWLEDGEMENTS
We thank Ellen Knapp, PhD, for editing the English text of a draft of this manuscript.

FOOTNOTES

Co-first authors: Xing-Nian Zhou and Quan Zhang.

Co-corresponding authors: Hong Li and Xin-Hua Luo.

Author contributions: Li H and Luo XH designed the study; Zhou XN, Zhang Q, Peng H, Qin YJ, and Liu YH were involved in the data collection; Zhou XN, Qin YJ, and Liu YH analyzed the data; Zhou XN, Zhang Q, Luo XH, and Li H drafted the manuscript; all authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. Zhou XN and Zhang Q contributed equally to this work as co-first authors. The reasons for designating Zhou XN and Zhang Q as co-first authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-first authors authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. Zhou XN and Zhang Q co-designed this study and worked together to explore the feasibility, innovativeness, and scientific validity of this study. Second, Zhou XN and Zhang Q worked together to complete the cell and animal parts of this study. In the process of the study, we encountered heavy problems, but we did not abandon each other or give up the study, but inspired and promoted each other. Without each other, we would not have been able to complete the study successfully. Third, Zhou XN and Zhang Q wrote the paper together. We collected and analysed the data, and then plotted them into graphs. We reviewed the literature and learnt from each other, thus successfully completing this paper. In summary, we believe that designating Zhou XN and Zhang Q as co-first authors is fitting for our manuscript as it accurately reflects our team’s collaborative spirit, equal contributions, and diversity. Luo XH and Li H contributed equally to this work as co-corresponding authors. Three aspects are described here to illustrate this. First, Luo XH and Li H jointly designed the study and completed the pilot experiments, which laid a solid foundation for the later experiments. Second, Luo XH and Li H worked together to help and solve the problems encountered during the study, thus facilitating the process of the study and finally completing it. When we encountered difficulties in our study and stopped moving forward, Luo XH and Li H provided us with valuable advice and research direction. When we wanted to give up, Luo XH and Li H inspired and motivated us. Under the leadership of Luo XH and Li H, we successfully achieved the current academic results. Third, Luo XH and Li H revised the current manuscript together, and Luo XH and Li H guided the framework structure of the paper. The paper could only be completed successfully under the tutelage of Luo XH and Li H. Luo XH and Li H played the roles of supervising, guiding, clearing doubts, and preaching throughout the study process.

Supported by National Natural Science Foundation of China, No. 82060123; Doctoral Start-up Fund of Affiliated Hospital of Guizhou Medical University, No. gysybsky-2021-28; Fund Project of Guizhou Provincial Science and Technology Department, No. [2020]1Y299; and Guizhou Provincial Health Commission, No. gzwj2019-1-082.

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Affiliated Hospital of
Guizhou Medical University.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Affiliated Hospital of Guizhou Medical University.

**Informed consent statement:** All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** The data presented in this study are available from the corresponding author upon reasonable request.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Xing-Nian Zhou 0000-0002-7569-9747; Yu-Jie Qin 0000-0002-9674-7492; Yu-Hong Liu 0000-0005-6346-7999; Lu Wang 0009-0008-7403-3434; Ming-Liang Cheng 0000-0002-2525-3595; Xin-Hua Luo 0000-0002-1140-2588; Hong Li 0000-0003-0601-3198.

**REFERENCES**
